Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.

De Hert, Marc, Detraux, Johan, van Winkel, Ruud, Yu, Weiping, Correll, Christoph U.·2012·Nature Reviews Endocrinology
DOI 10.1038/nrendo.2011.156

Cited by (1,000)

Items 901–1,000 of 1,000

  1. Psychopharmakotherapie und metabolische Nebenwirkungen
    R. Zeiss, B. Connemann, M. Gahr · 2017 · Nervenheilkunde
  2. Diabetogenic Effects Associated with Psychiatric Treatment
    Vasiliki Mamakou, Ioanna Eleftheriadou, Anastasios Tentolouris, Nikolaos Sabanis, Aikaterini Drylli, Nikolaοs Tentolouris · 2018 · Current Pharmacology Reports
  3. Integrating Physical Activity Into Routine Medical Care
    Martha Ward, Aniyizhai Annamalai, Lydia Chwastiak · 2018 · Elsevier eBooks
  4. Soluble dietary fiber fraction of Trigonella foenum graecum seeds prevent olanzapine induced metabolic syndrome in rats
    Ajay Singh Kushwah · 2018 · MOJ Drug Design Development & Therapy
  5. Assessment of cardiovascular risk for serious mental disorders (tur)
    Rugül Köse Çınar, Pelin Taş Dürmüş · 2019 · Journal of Clinical Psychiatry
  6. Lipid Metabolism Disturbances During Antipsychotic Treatment for Schizophrenia
    Shin Ono, Toshiyuki Someya · 2021 · Springer eBooks
  7. Schizophrenie
    BENNO GRAF SCHIMMELMANN, Claudia Mehler‐Wex, Christoph Wewetzer · 2016 · Springer eBooks
  8. Evaluating the Effectiveness of Joint Specialist Case Conferences in Improving Diabetes Control in Patients With Schizophrenia on Clozapine
    Yu Zheng, Gideon Meyerowitz‐Katz, Sian Bramwell, Rajini Jayaballa, Yolinda Assur, Deepali Vasani, Ramanathan Ganapathy, GLEN F. MABERLY, Vlasios Brakoulias · 2022 · The Journal of Nervous and Mental Disease
  9. Efficacy and Safety of Second-generation Antipsychotics in Schizophrenia Pharmacotherapy: A Comparative Narrative Review
    Mohamed Hassan Elnaem · 2022 · Malaysian Journal of Medicine and Health Sciences
  10. Andere spezifische Diabetesformen und exokrine Pankreasinsuffizienz (Update 2023)
    Susanne Kaser, Sabine E. Hofer, Lili Kazemi-Shirazi, Andreas Festa, Yvonne Winhofer, Harald Sourij, Helmut Brath, Michaela Riedl, Michael Resl, Martin Clodi et al. · 2023 · Wiener klinische Wochenschrift
  11. Revisão clínica
    Daiane Maria Cordeiro, Guilherme Antoniacomi Pereira, Rafael Nunes Borges · 2023 · Revista Brasileira de Medicina de Família e Comunidade
  12. Lurasidone blocks the voltage-gated potassium channels of coronary arterial smooth muscle cells
    Wenwen Zhuang, Seo‐Yeong Mun, Minju Park, Junsu Jeong, Hongzoo Park, Sunghun Na, Se Jin Lee, Won‐Kyo Jung, Il‐Whan Choi, Hongliang Li et al. · 2023 · European Journal of Pharmacology
  13. Barriers, Facilitators, and Experiences of Physical Exercise Programs in Outpatient Mental Health Services
    Álvaro López-Moral, Diego Munguía‐Izquierdo, Javier Bueno‐Antequera · 2023 · Advances in psychology, mental health, and behavioral studies (APMHBS) book series
  14. Exploring the Role of Physical Exercise to Improve Cardiorespiratory Fitness and Muscular Strength Among Individuals With Severe Mental Disorder
    Álvaro López-Moral, Diego Munguía‐Izquierdo, Javier Bueno‐Antequera · 2023 · Advances in psychology, mental health, and behavioral studies (APMHBS) book series
  15. Shaping research for people living with co‐existing mental and physical health conditions: A research priority setting initiative from the United Kingdom
    Olivia Taylor, Elizabeth Newbronner, Helen Cooke, Lauren E. Walker, Ruth Wadman · 2024 · Health Expectations
  16. Risk of Cardiovascular Events in Schizophrenic Patients Treated with Paliperidone Palmitate Once-Monthly Injection (PP1M): A Population-Based Retrospective Cohort Study in Taiwan
    Shih‐Pei Shen, Yan Li, Tao Wu, Min‐Wei Huang, Kuan‐Chih Huang, Hong Xia Qiu, Yongjing Zhang, Chao‐Hsiun Tang · 2024 · Clinical Drug Investigation
  17. Therapeutic monitoring of antipsychotics with a focus on lurasidone and its dosing
    Zuzana Strašilová, Miroslav Turjap, Jan Juřica · 2023 · Česká a slovenská farmacie
  18. Effect of GLP-1 receptor agonists on obesity in patients with severe mental illness: A state hospital case series of clozapine-treated patients
    Syed Sadat Ali, Narges Ghodsimaab, Matthew Rusling, Navid Rashid · 2024 · Psychiatry Research Case Reports
  19. Bibliometric Analysis of Antipsychotic-induced Metabolic Disorder from 2006 to 2021 Based on WoSCC Database
    Zhihao Guo, Zi Meng Zhang, Lu Li, Ming Zhang, Shanqing Huang, Zezhi Li, Dewei Shang · 2025 · Current Neuropharmacology
  20. Clinical protocol for nutritional screening in autism (PANA): a cross-sectional study protocol
    Juliana dos Santos Vaz, Sandra Costa Valle, Eduarda de Souza Silva, Laura Vargas Hoffmann, Josiane da Cunha Luçardo, Juliana Costa Maia, Luiza Vieira da Silva Magalhães, Kamila Castro Grokoski · 2025 · BMJ Open
  21. “Well-Track” Healthy Lifestyle Coaching in Severe Mental Illness: A Qualitative Study Exploring Participant Experience and Impact
    Alice Sheldon, Chris Griffiths, Ema Baukaite, Kate Walker · 2025 · Open Journal of Preventive Medicine
  22. Concurrence of clozapine-induced diabetic ketoacidosis and neuroleptic malignant syndrome: A case report
    Min Hyeok Shin, Jin Woo Jeong, Tae Yang Yu · 2025 · Medicine
  23. Safety profile of olanzapine/samidorphan: focus on metabolic risks, opioid-related effects, and novel adverse events identified
    Xiangyu Li, Lingjing Yuan, J. Li · 2025 · Naunyn-Schmiedeberg s Archives of Pharmacology
  24. Clinical Pharmacogenetics of Olanzapine : with Focus on FMO Gene Polymorphisms
    Mao Mao Söderberg · 2012
  25. Mécanismes des effets diabétogènes des médicaments antipsychotiques
    Bruno Fève · 2015 · Médecine des Maladies Métaboliques
  26. Development of novel therapy of schizophrenia in children and adolescents
    Corinna Klein, Anton Bespalov · 2014 · Expert Opinion on Investigational Drugs
  27. Insulin resistance in major depressive disorder and the effects of psychotropic medications
    Jennifer S Mason, Heather A. Kenna, Natalie Rasgon · 2012 · Clinical Practice
  28. Antipsychotika im Kindes- und Jugendalter: pro und contra
    Klaus Schmeck · 2015 · Praxis
  29. Anti-Psychotic Medication and the Pattern of Cardiovascular Risk Factors: A Population Based Study (The Ayrshire Diabetes Follow-Up Cohort (ADOC) Study)
    Lee Euan Sit, Mario D. Hair, Lyall Cameron, Andrew Collier, Ammar Abdeen, Karthigayan Kessavalou · 2017 · Journal of Addiction Research & Therapy
  30. Lifestyle Interventions in Patients With Serious Mental Illness
    Aaron Gluth, DeJuan T. White, Martha Ward · 2018 · Elsevier eBooks
  31. Biomarkers for “Cause of Death”
    Takako Sato, Koichi Suzuki · 2018 · Current human cell research and applications
  32. Metabolic Side Effects of Antipsychotic Medication: An Overview
    Jung Sun Lee · 2019 · 신경정신의학
  33. A New Plea to Focus on the End-of-Life Needs of People with Severe Mental Illnesses
    Katrin Gerber, Rachael Craanen, Natalie James, Steven M. Savvas, Barbara Hayes, Bianca Brijnath · 2019 · Issues in Mental Health Nursing
  34. Metabolic dysregulation in early onset psychiatric disorder before and after exposure to antipsychotic drugs
    Rehmat Shah, Fazal Subhan, Syed Muhammad Sultan, Matiul Haq, Hussain Ahmad, Qasim Riaz Khan, Gowhar Ali, Sami Ullah, Ihsan Ullah · 2019 · Brazilian Journal of Pharmaceutical Sciences
  35. A Brief Guide to Medications for Psychosis
    Anthony W.F. Harris · 2019 · Elsevier eBooks
  36. Hyperglycemic Crises
    Francisco J. Pasquel, Guillermo E. Umpierrez · 2015 · Elsevier eBooks
  37. Hyperglycemia Secondary to Nondiabetic Conditions and Therapies
    Harold E. Lebovitz · 2015 · Elsevier eBooks
  38. Psychotic Disorders and Risk-States in Adolescence: Etiology, Developmental Considerations, and Treatment
    Tina Gupta, Katherine S. F. Damme, Kenneth Juston Osborne, Teresa Vargas, Ivanka Ristanovic, Isabelle R. Frosch, Vanessa C. Zarubin, Kasia Hitczenko, Trevor F. Williams, Henry Raffles Cowan et al. · 2021 · Elsevier eBooks
  39. Design and pilot evaluation of an evidence-based worksheet and clinician guide to facilitate nutrition counselling for patients with severe mental illness
    Laura LaChance, Monique Aucoin, Kieran Cooley · 2021 · BMC Psychiatry
  40. Favourable cognitive changes observed with metabolic improvements in a patient with severe mental illness
    Emma Alaine van Reekum, Nicolette Stogios, Leah Burton, Harold Spivak, Margaret Hahn, Sri Mahavir Agarwal · 2023 · Journal of Psychiatry and Neuroscience
  41. Clinical Evaluation for Genetic and Secondary Causes of Dyslipidemia
    Julia C. Creider, Robert Alexander Hegele · 2015 · Elsevier eBooks
  42. Cardiovascular risk factors and pharmacogenetics of clozapine in schizophrenia
    Eric Olsson · 2015 · Figshare
  43. G. Smedslund og C. Stoltenberg svarer
    Geir Smedslund, Camilla Stoltenberg · 2018 · Tidsskrift for Den norske legeforening
  44. The first patient to receive olanzapine: A recollection
    David S. Baldwin · 2021 · Human Psychopharmacology Clinical and Experimental
  45. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor -dependent and -independent pathways
    Wenqiang Zhu, Piaopiao Huang, Rong Li, Juanli Ran, Wen Dai, Yaxin Tang, Pingan Lian, Chen Ding, Xiansheng Huang · 2022 · Research Square
  46. Management of Antipsychotics in Primary Care: Insights from Healthcare Professionals and Policy Makers in the UK
    Alan Woodall, Aseel S. Abuzour, Samantha A. Wilson, Frances S Mair, Iain Edward Buchan, Sally B. Sheard, Paul Atkinson, Dan W. Joyce, Pyers Symon, Lauren Elizabeth Walker · 2023 · medRxiv
  47. Movement disorders in psychiatry as symptom, as side effect, and as risk factor
    Anne E. Willems · 2023
  48. Long-Term Effects of Early Adolescent Second-Generation Antipsychotic Exposure on Body Weight, Caloric Intake, and Metabolism-Associated Gene Expression
    Paul L. Soto, Michael E. Young, Serena Nguyen, Megan Federoff, Mia M Goodson, Christopher D. Morrison, Heidi M. Batdorf, Susan J. Burke, J. Jason Collier · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  49. Áhrif hreyfiíhlutunar á einkenni geðklofa, andlega líðan og líkamssamsetningu hjá ungu fólki
    Kristjana Sturludóttir, Sunna Gestsdóttir, Rafn Haraldur Rafnsson, Erlingur Jóhannsson · 2015 · Læknablaðið
  50. Clinical and Ethical Conflicts in Diagnosing and Treating Behavioral Problems in Children
    Matthew A. Butkus, Matthew S. Mutchler · 2012
  51. Schwere psychische Erkrankungen und Diabetes mellitus Typ-2
    De Hert, Marc, Johan Detraux, Davy Vancampfort, Correll, Chistopher · 2012 · Lirias
  52. Comparing tolerability profile of second generation antipsychotics in schizophrenia and affective disorders : a meta-analysis
    Hoda Moteshafi · 2011
  53. A case of hypertriglyceridemia risperidone-induced
    Daniela Maria Oliani, Ester Messina, Valentina Ciappolino, Luca Tarantola · 2013 · Università degli Studi di Pavia
  54. Some novelties and recommendations by swithing antipsychotics
    Nika Aleksandra Kravos, Matej Kravoš · 2014 · DOAJ (DOAJ: Directory of Open Access Journals)
  55. Dynamics of drug evaluation: Formulary placement of antipsychotics
    Cynthia A. Mascareñas, Rosana Oliveira · 2013 · Mental Health Clinician
  56. PS1-16: Directions for Future Patient-Centered and Comparative Effectiveness Research for People with Serious Mental Illness
    C. Green, Sue E. Estroff, Bobbi Jo H. Yarborough, Mark Spofford, Michele R. Solloway, Nancy Perrin · 2013 · Clinical Medicine & Research
  57. Ask the Expert: Schizophrenia
    Christoph Ulrich Correll · 2012 · FOCUS The Journal of Lifelong Learning in Psychiatry
  58. Changes of Body Weight and Metabolic Syndrome in Psychiatric Inpatients
    Woo Young Jang, Kwang‐Hun Lee, Nari Bae, Sung-Min Lee, Tae‐Woo Kim, Jung-Kyu Sakong, Kyung‐Phil Kwak · 2014
  59. Blood-based Biomarkers for Personalised Medicine Applications in Schizophrenia
    Jakub Tomasik · 2014 · EUR Research Repository (Erasmus University Rotterdam)
  60. Determinantes del aumento de peso producido por los antipsicóticos: un estudio de cohortes
    Verónica Velasco · 2016
  61. Psychiatric Pharmacotherapy in Coronary Artery Disease Patients
    Roberto Latini, Silvio K. Garattini · 2016 · Springer eBooks
  62. Pediatric Psychopharmacology: a Primer for the Treatment of Common Mental Health Conditions
    Mary Margaret Gleason · 2017 · Current Treatment Options in Pediatrics
  63. Clinical Factors Associated with Weight Gain in French-Canadian Children and Adolescents Treated With Second Generation Antipsychotics: A 24-Month Retrospective Study
    Leila Ben Amor · 2017 · Current Research in Diabetes & Obesity Journal
  64. Platelet count in elderly patients with unipolar depression – case control analysis
    Adam Wysokiński, Krzysztof Socha, Bartłomiej Konrad Sołtysik, Iwona Kłoszewska, Tomasz Sobów, Tomasz Kostka · 2018 · Psychiatria i Psychologia Kliniczna
  65. Mobility for All?
    Claudine Higdon, Christoph Ulrich Correll, Stephen Crystal, Nick C. Patel, Melissa P. DelBello · 2018 · Journal of the American Academy of Child & Adolescent Psychiatry
  66. Comparative Safety Profile of Single Versus Combination Antipsychotic Therapy by Using Glassgow Antipsychotic Side Effect Scale (Gass)
    S Zikria · 2017 · Neurology & Neurotherapy Open Access Journal
  67. Prevalence of metabolic syndrome in a population served by assertive community treatment teams: a retrospective chart review
    Jonathan Fairbairn, Tariq A Munshi, Farooq Naeem, Jane Baldock, Martin Feakins · 2018 · Clinical Audit
  68. Computational Approaches for Identification of Pleiotropic Biomarker Profiles in Psychiatry
    Han Cao, Emanuel Schwarz · 2019 · Advances in experimental medicine and biology
  69. THE ROLE OF EXERCISE IN REDUCING THE SIDE EFFECTS OF ANTIPSICOTICS USED IN THE TREATMENT OF BIPOLAR DISORDERS
    HATİCE TOY, Erkut Tutkun, Itır Tarı Cömert · 2019 · Turkish Journal of Sport and Exercise
  70. Atypical Antipsychotics and Dyslipidemia- Experience at Psychiatry Hospital Hyderabad, Pakistan.
    Quratulain Khuhro, Naseem Aslam Channa, Safdar Ali Amur, Muzna Para, Muhammad Haneef Mugheri, Najaf Ali Soomro · 2018 · Annals of King Edward Medical University
  71. Stranded on Antipsychotics: Role of the Pediatric Clinician
    Rachel Ballard, Nia Heard‐Garris · 2019 · Clinical Pediatrics
  72. Clozapine Administration Potentiate Platelet Activation in Patients with Schizophrenia : Retrospective Study
    김현아, 이종욱, Kim Seung Jun, Hong Seok Oh, Im Wooyoung, Ji‐Woong Kim · 2018
  73. Antipsychotics and Cardiac Side Effects
    Annamaria Mascolo, Cristina Scavone, Concetta Rafaniello, Annalisa Capuano · 2019 · Springer eBooks
  74. Effectively Assessing Sleep and Circadian Rhythms in Psychosis
    Jan Cosgrave, Elizabeth A. Klingaman, Philip Gehrman · 2019 · Elsevier eBooks
  75. Effects of neuroleptics and antidepressants on the cardiovascular system: literature review
    Vilius Rutkauskas · 2019 · Neurologijos seminarai
  76. The Relative Risk of Developing Type 2 Diabetes Mellitus in Young Adults with Schizophrenia Treated with Different Atypical Antipsychotic
    Nicolae-Marius Cason, Petru Aurel Babeș, Enikő Béres, Katalin Babeș · 2019 · Romanian Journal of Diabetes Nutrition and Metabolic Diseases
  77. Interaction between the immune and metabolic systems in different stages of schizophrenia spectrum disorders
    Roman Balõtšev · 2020 · DSpace repository (University of Tartu)
  78. Cardiovascular Manifestations in Schizophrenia
    Federica Calorio, Cristina Grazia Catania, Matteo Rocchetti · 2020 · Springer eBooks
  79. Development and implementation of clozapine protocol in patients with schizophrenia in Greece
    Maria Nystazaki, Maria N. K. Karanikola, V. Gartzoni, A. Georgou, St. Tolia, Chr. Liapis, M. Psomiadi, Giorgos Alevizopoulos · 2020 · Psychiatriki
  80. 일 대학병원 정신건강의학과 입원 환자의 체중 및 대사증후군의 변화
    장우영, 이광헌, 배나리, 이성민, 김태우, 사공정규, 곽경필 · 2014 · 대한정신약물학회지
  81. P.182 Metabolic syndrome in patients with schizophrenia and the PTPN5 gene encoding the striatal-enriched protein tyrosine phosphatase
    Diana Z. Paderina, Anastasiia S. Boiko, Ivan V. Pozhidaev, Elena G. Kornetova, S. Ivanova · 2020 · European Neuropsychopharmacology
  82. P.541 Inflammation in schizophrenia with metabolic syndrome: features of the cytokine spectrum
    Anastasiia S. Boiko, Elena G. Kornetova, ANTON J. M. LOONEN, Svetlana А. Ivanova · 2020 · European Neuropsychopharmacology
  83. Mortality Risk of Antipsychotic Augmentation for Adult Depression
    Tobias Gerhard, T. Scott Stroup, Christoph Ulrich Correll, Soko Setoguchi, Brian L. Strom, Cecilia S. Huang, Zhiqiang Tan, Stephen Crystal, Mark Olfson · 2021 · FOCUS The Journal of Lifelong Learning in Psychiatry
  84. Obesity and schizophrenia: New drugs, new hopes
    Čedo Miljević, Olivera Vuković · 2020 · Psihijatrija danas
  85. Reducing metabolic syndrome in Australian patients: Metabolic Management During Antipsychotic Prescribing (MMAP) programme
    David Jonathan Castle, Malcolm Hopwood, Sanil Rege, David B George · 2021 · Australasian Psychiatry
  86. WPW Induced Ventricular Tachycardia in a Patient Using Quetiapine
    Adem Kaya · 2021 · Phoenix Medical Journal
  87. Studies on Prediction Systems for Revealing Biological Functions of Drug Candidates
    保則 福田, Yasunori Fukuda · 2019 · Terrestrial Environment Research Center (University of Tsukuba)
  88. Olanzapine: Association Between a Typical Antipsychotic Drug and Aortic Calcification
    Chao Zhang, Dongdong Zheng, Weijing Feng, Huanji Zhang, Feng Han, Wanbing He, Aiting Liu, Hui Huang, Jie Chen · 2021 · Frontiers in Cardiovascular Medicine
  89. Lurasidone Switching in Patients with Schizophrenia Who Showed Suboptimal Effect and/or Intolerability to Current Antipsychotics
    Shih‐Ku Lin, Chin‐Bin Yeh, Katsuhiko Hagi · 2021 · Taiwanese Journal of Psychiatry
  90. Clinical Characteristics of Patients with Schizophrenia Maintained without Antipsychotics: A Cross-sectional Survey of a Case Series
    Hideaki Tani, Masayuki Tomita, Takefumi Suzuki, Masaru Mimura, Hiroyuki Uchida · 2021 · Clinical Psychopharmacology and Neuroscience
  91. The Electrophysiological Correlates of Morphological Priming in Language Production
    Dirk Koester, Rick Giesbers, Niels Olaf Schiller · 2007 · Max Planck Digital Library
  92. Effect of depression and anxiety on quality of life among cardiovascular patients visiting Tertiary Care hospital Lahore
    Andleeb Shakoor, Hafsa Kamran, Maryam Shakoor, Sidra Khalid, Sughra Shakoor, Maria Aslam, Hina Shakoor · 2021 · Pakistan BioMedical Journal
  93. P.0606 Identification of key genes involved in antipsychotic-induced metabolic dysregulation based on integrative bioinformatics analysis of multi-tissue gene expression data
    Patricia Gassó, Albert Martínez-Pinteño, L. Prohens, Àlex G. Segura, Mara Parellada, Pilar Alejandra Sáiz, Miguel Cuesta, Miquel Bernardo, Amàlia Lafuente, Sergi Mas et al. · 2021 · European Neuropsychopharmacology
  94. P.0176 Gene polymorphisms of hormones regulating metabolism in schizophrenia patients with metabolic syndrome
    Anastasiia S. Boiko, Ivan V. Pozhidaev, Diana Z. Paderina, Elena G. Kornetova, Svetlana А. Ivanova · 2021 · European Neuropsychopharmacology
  95. Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkankungen, 9. Auflage
    2013 · Elsevier eBooks
  96. Pharmacological interventions for reduction of weight gain in people with schizophrenia
    Margaret Hahn, Sri Mahavir Agarwal, Zohra A Ahsan, Jonathan Lockwood, Markus J. Duncan, Hiroyoshi Takeuchi, Tony A. Cohn, Valerie H. Taylor, Gary J. Remington, Guy Faulkner · 2019 · Cochrane Database of Systematic Reviews
  97. Cardiovascular Manifestations in Schizophrenia
    Federica Calorio, Cristina Grazia Catania, Matteo Rocchetti · 2020 · Springer eBooks
  98. Psychoneurobiology Research and Personalized Treatment of Schizophrenia
    Tomiki Sumiyoshi · 2022 · MDPI eBooks
  99. Bibliography: Psychopharmacology: Evidence and Treatments
    2014 · FOCUS The Journal of Lifelong Learning in Psychiatry
  100. Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 13. Auflage
    2017 · Elsevier eBooks